Analyst Research: Regeneron Pharmaceuticals Inc (REGN.OQ)
REGN.OQ on NASDAQ Stock Exchange Global Select Market
271.42USD
12:55pm EDT
271.42USD
12:55pm EDT
Price Change (% chg)
$-6.87 (-2.47%)
$-6.87 (-2.47%)
Prev Close
$278.29
$278.29
Open
$277.64
$277.64
Day's High
$277.64
$277.64
Day's Low
$271.36
$271.36
Volume
68,696
68,696
Avg. Vol
220,530
220,530
52-wk High
$283.00
$283.00
52-wk Low
$131.50
$131.50
| Name | Age | Since | Current Position |
|---|---|---|---|
P. Roy Vagelos |
83 | 1995 | Chairman of the Board |
Leonard Schleifer |
60 | 1994 | President, Chief Executive Officer, Director |
Murray Goldberg |
68 | 2000 | Chief Financial Officer, Senior Vice President - Finance and Administration, Assistant Secretary |
Joseph LaRosa |
54 | 2011 | Senior Vice President, General Counsel, Secretary |
Daniel Van Plew |
40 | 2008 | Senior Vice President, General Manager - Industrial Operations and Product Supply |
- UK cost agency recommends Bayer, Regeneron eye drug
- Regeneron settles all pending litigation with Roche's Genentech
- FEATURE-Fast climbing biotech Regeneron still has room to grow
- UPDATE 2-Regeneron raises Eylea sales view, shares hit all-time high
- Regeneron raises 2013 Eylea sales view, profit beats Street

